Sangamo Therapeutics (Sangamo Therapeutics) EV-to-EBIT

Array ( [0] => - [1] => - [2] => - [3] => - [4] => - [5] => -6.21 [6] => -12.48 [7] => -4.18 [8] => -1.44 [9] => -0.45 )

Sangamo Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT							-6.21	-12.48	-4.18	-1.44	-0.45

Sangamo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT																-1.44	-1.70	-1.17	-0.08	-0.45

For the Biotechnology subindustry, Sangamo Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

For the Biotechnology industry and Healthcare sector, Sangamo Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sangamo Therapeutics's EV-to-EBIT falls into.

Sangamo Therapeutics EV-to-EBIT Calculation

Sangamo Therapeutics's EV-to-EBIT for today is calculated as:

Sangamo Therapeutics's current Enterprise Value is $55.9 Mil.
Sangamo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics  (NAS:SGMO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sangamo Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Sangamo Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $53.9 Mil.
Sangamo Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-119.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sangamo Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sangamo Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sangamo Therapeutics (Sangamo Therapeutics) Business Description